{"id":73485,"date":"2026-04-17T16:11:09","date_gmt":"2026-04-17T10:41:09","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=73485"},"modified":"2026-04-17T16:11:11","modified_gmt":"2026-04-17T10:41:11","slug":"panacea-biotec-q4-results-2026-preview","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/","title":{"rendered":"Panacea Biotec Q4 Results 2026: Date, Revenue, PAT And Analyst Outlook"},"content":{"rendered":"<p>Panacea Biotec (NSE: PANACEABIO) is preparing to announce its Q4 FY26 financial results for the quarter ended March 31, 2026. With Panacea Biotec trading at Rs 328 \u2014 against a 52-week high of Rs 520 and a 1-year return of -30% \u2014 the Q4 FY26 results will be a pivotal event for investors tracking the Pharma\/Vaccines sector.<\/p><p>Analyst estimates for Q4 FY26 revenue stand at Rs 280\u2013320 Cr, with PAT expectations of Rs 18\u201328 Cr and margin projections of EBITDA 12\u201316%. This article covers the Panacea Biotec Q4 results 2026 date, detailed earnings estimates, five key performance factors, five risks to monitor, analyst ratings, and answers to the most commonly searched investor questions.<\/p><p>Get free investment predictions on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#Panacea_Biotec_Q4_Results_2026_Date\" title=\"Panacea Biotec Q4 Results 2026 Date\">Panacea Biotec Q4 Results 2026 Date<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#Why_This_Quarter_Matters\" title=\"Why This Quarter Matters\">Why This Quarter Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#Panacea_Biotec_Q4_FY26_Earnings_Estimates\" title=\"Panacea Biotec Q4 FY26 Earnings Estimates\">Panacea Biotec Q4 FY26 Earnings Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#5_Key_Factors_That_Will_Drive_Panacea_Biotec_Q4_FY26_Performance\" title=\"5 Key Factors That Will Drive Panacea Biotec Q4 FY26 Performance\">5 Key Factors That Will Drive Panacea Biotec Q4 FY26 Performance<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#Revenue_Growth_Drivers_in_PharmaVaccines\" title=\"Revenue Growth Drivers in Pharma\/Vaccines\">Revenue Growth Drivers in Pharma\/Vaccines<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#Margin_Expansion_and_Operating_Leverage\" title=\"Margin Expansion and Operating Leverage\">Margin Expansion and Operating Leverage<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#Working_Capital_Management_and_Cash_Conversion\" title=\"Working Capital Management and Cash Conversion\">Working Capital Management and Cash Conversion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#FY27_Guidance_and_Business_Pipeline\" title=\"FY27 Guidance and Business Pipeline\">FY27 Guidance and Business Pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#Competitive_Positioning_and_Market_Share\" title=\"Competitive Positioning and Market Share\">Competitive Positioning and Market Share<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#5_Risks_to_Watch_in_Panacea_Biotec_Q4_FY26\" title=\"5 Risks to Watch in Panacea Biotec Q4 FY26\">5 Risks to Watch in Panacea Biotec Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#Macroeconomic_Headwinds_and_Demand_Risk\" title=\"Macroeconomic Headwinds and Demand Risk\">Macroeconomic Headwinds and Demand Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#Input_Cost_and_Supply_Chain_Volatility\" title=\"Input Cost and Supply Chain Volatility\">Input Cost and Supply Chain Volatility<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#Competitive_Pressure_and_Pricing_Risk\" title=\"Competitive Pressure and Pricing Risk\">Competitive Pressure and Pricing Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#Governance_and_Reporting_Quality_Risk\" title=\"Governance and Reporting Quality Risk\">Governance and Reporting Quality Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#FY27_Guidance_Risk_and_Estimate_Revision\" title=\"FY27 Guidance Risk and Estimate Revision\">FY27 Guidance Risk and Estimate Revision<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#Panacea_Biotec_Share_Price_and_Analyst_Ratings\" title=\"Panacea Biotec Share Price and Analyst Ratings\">Panacea Biotec Share Price and Analyst Ratings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#What_is_the_Panacea_Biotec_Q4_results_2026_date\" title=\"What is the Panacea Biotec Q4 results 2026 date?\">What is the Panacea Biotec Q4 results 2026 date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#What_is_the_Panacea_Biotec_Q4_FY26_PAT_estimate\" title=\"What is the Panacea Biotec Q4 FY26 PAT estimate?\">What is the Panacea Biotec Q4 FY26 PAT estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#What_is_Panacea_Biotecs_share_price_ahead_of_Q4_results\" title=\"What is Panacea Biotec&#8217;s share price ahead of Q4 results?\">What is Panacea Biotec&#8217;s share price ahead of Q4 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#Will_Panacea_Biotec_declare_a_dividend_in_Q4_2026\" title=\"Will Panacea Biotec declare a dividend in Q4 2026?\">Will Panacea Biotec declare a dividend in Q4 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#Which_analysts_have_a_Buy_rating_on_Panacea_Biotec\" title=\"Which analysts have a Buy rating on Panacea Biotec?\">Which analysts have a Buy rating on Panacea Biotec?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#What_were_Panacea_Biotec_Q3_FY26_results\" title=\"What were Panacea Biotec Q3 FY26 results?\">What were Panacea Biotec Q3 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#When_do_Infosys_and_TCS_announce_Q4_results_2026\" title=\"When do Infosys and TCS announce Q4 results 2026?\">When do Infosys and TCS announce Q4 results 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#Is_Panacea_Biotec_a_good_investment_ahead_of_Q4_results\" title=\"Is Panacea Biotec a good investment ahead of Q4 results?\">Is Panacea Biotec a good investment ahead of Q4 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/panacea-biotec-q4-results-2026-preview\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Panacea_Biotec_Q4_Results_2026_Date\"><\/span><strong>Panacea Biotec Q4 Results 2026 Date<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>Q4 FY26 Results Date<\/strong><\/td><td><strong>Sector<\/strong><\/td><\/tr><tr><td>TCS<\/td><td>April 9, 2026<\/td><td>IT Services<\/td><\/tr><tr><td>Infosys<\/td><td>April 23, 2026<\/td><td>IT Services<\/td><\/tr><tr><td>Panacea Biotec<\/td><td>May 2026 (Expected)<\/td><td>See article<\/td><\/tr><\/tbody><\/table><\/figure><p>Panacea Biotec has scheduled its Q4 FY26 results for May 2026 (Expected). The board of directors will meet to approve audited financial statements for the quarter ended March 31, 2026, and to consider a final dividend recommendation. At a CMP of Rs 328, investors will closely watch this announcement for revenue growth confirmation and FY27 guidance.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_This_Quarter_Matters\"><\/span><strong>Why This Quarter Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Q4 FY26 is the final quarter of the financial year \u2014 it determines full-year FY26 performance, sets the FY27 estimate base, and triggers final dividend announcements. For Panacea Biotec, operating in the Pharma\/Vaccines sector, Q4 will reveal whether earlier-quarter momentum has sustained and whether management&#8217;s strategic initiatives are delivering measurable financial outcomes.<\/p><p>At a 1-year return of -30%, the Q4 FY26 results and FY27 guidance commentary will be critical in determining whether the stock can recover toward its 52-week high of Rs 520. Investors will focus on order book updates, margin trajectory, and management tone \u2014 positive surprises on multiple parameters could drive a meaningful re-rating.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Panacea_Biotec_Q4_FY26_Earnings_Estimates\"><\/span><strong>Panacea Biotec Q4 FY26 Earnings Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"776\" height=\"405\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160807\/image-1088.jpeg\" alt=\"Panacea Biotec Q4 FY26 Analyst Estimates at a Glance | Source: MOFSL, YES Securities, JM Financial\" class=\"wp-image-73489\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160807\/image-1088.jpeg 776w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160807\/image-1088-300x157.jpeg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160807\/image-1088-768x401.jpeg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160807\/image-1088-600x313.jpeg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160807\/image-1088-150x78.jpeg 150w\" sizes=\"(max-width: 776px) 100vw, 776px\" \/><\/figure><p>Access premium SEBI-registered research on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><p>Analysts covering Panacea Biotec have published Q4 FY26 estimates reflecting sector trends and company-specific catalysts. Consensus points to revenue of Rs 280\u2013320 Cr, PAT of Rs 18\u201328 Cr, and margins of EBITDA 12\u201316%. These projections incorporate Q4 seasonal strength and ongoing business improvements.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q3 FY26 Actual<\/strong><\/td><td><strong>Q4 FY26 Estimate<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 255 Cr<\/td><td>Rs 280\u2013320 Cr<\/td><\/tr><tr><td>PAT<\/td><td>Rs 15 Cr<\/td><td>Rs 18\u201328 Cr<\/td><\/tr><tr><td>Margin<\/td><td>EBITDA 13.5%<\/td><td>EBITDA 12\u201316%<\/td><\/tr><tr><td>Growth Driver<\/td><td>Base quarter<\/td><td>Recovery catalyst<\/td><\/tr><tr><td>Dividend<\/td><td>Rs 3 per share<\/td><td>Rs 2\u20133 per share<\/td><\/tr><\/tbody><\/table><\/figure><p>Beyond headline numbers, investors should monitor FY27 guidance commentary, working capital trends, and order book visibility. A clean recurring profit print \u2014 rather than one inflated by non-operational items \u2014 carries greater weight with long-term investors.<\/p><p>Screen <a href=\"https:\/\/univest.in\/screeners\">Panacea Biotec<\/a> fundamentals on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Key_Factors_That_Will_Drive_Panacea_Biotec_Q4_FY26_Performance\"><\/span><strong>5 Key Factors That Will Drive Panacea Biotec Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Revenue_Growth_Drivers_in_PharmaVaccines\"><\/span><strong>Revenue Growth Drivers in Pharma\/Vaccines<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Panacea Biotec&#8217;s Q4 FY26 revenue estimate of Rs 280\u2013320 Cr reflects sector-level demand recovery and company-specific execution. Q4 is seasonally the strongest quarter for most Indian businesses due to year-end order execution and government spending acceleration. Panacea Biotec&#8217;s ability to capitalise on these tailwinds will depend on operational capacity, client relationships, and pricing power within its competitive landscape.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Margin_Expansion_and_Operating_Leverage\"><\/span><strong>Margin Expansion and Operating Leverage<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Panacea Biotec&#8217;s Q4 FY26 margin estimate of EBITDA 12\u201316% embeds expected improvement as fixed costs are absorbed over a growing revenue base. Smaller and mid-cap companies often demonstrate disproportionate EBITDA expansion when quarterly revenues scale even modestly. Management cost discipline \u2014 particularly on employee expenses, power, and overheads \u2014 will determine the degree of margin recovery.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Working_Capital_Management_and_Cash_Conversion\"><\/span><strong>Working Capital Management and Cash Conversion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>For Panacea Biotec operating in the Pharma\/Vaccines segment, working capital efficiency is a critical determinant of financial health. Q4 FY26 results will reveal debtor days, inventory levels, and net cash conversion cycle. Any improvement in collections and receivables management would signal better business quality and reduce dependence on short-term borrowing.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FY27_Guidance_and_Business_Pipeline\"><\/span><strong>FY27 Guidance and Business Pipeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Management commentary on FY27 business outlook \u2014 however informally delivered for smaller companies \u2014 will be as important as Q4 headline numbers. New client wins, order book updates, geographic expansion plans, and product pipeline disclosures provide investors with forward visibility that shapes stock price trajectory into FY27.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Competitive_Positioning_and_Market_Share\"><\/span><strong>Competitive Positioning and Market Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Panacea Biotec&#8217;s Q4 FY26 performance reflects its ability to hold or gain competitive ground in the Pharma\/Vaccines sector. Market share stability, pricing power, and client retention metrics are the key qualitative indicators that separate sustainable performance from one-off beats. Any evidence of market share gains \u2014 however marginal \u2014 would be a strongly positive qualitative signal.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Risks_to_Watch_in_Panacea_Biotec_Q4_FY26\"><\/span><strong>5 Risks to Watch in Panacea Biotec Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Macroeconomic_Headwinds_and_Demand_Risk\"><\/span><strong>Macroeconomic Headwinds and Demand Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The April 2026 US tariff shock and global uncertainty have created headwinds for Indian equities through FII outflows and compressed demand in export-linked sectors. For Panacea Biotec, indirect impacts include input cost pressure, sentiment-driven selling, and potential softening of client capex budgets. Any deterioration in macro conditions for Q1 FY27 would require analyst estimate revisions.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Input_Cost_and_Supply_Chain_Volatility\"><\/span><strong>Input Cost and Supply Chain Volatility<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Panacea Biotec&#8217;s cost structure in the Pharma\/Vaccines space is exposed to raw material price movements and supply chain disruptions. Any reversal in the commodity price trends embedded in Q4 estimates \u2014 whether crude, metals, chemicals, or agricultural inputs \u2014 could compress gross margins and disappoint PAT expectations despite revenue in-line performance.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Competitive_Pressure_and_Pricing_Risk\"><\/span><strong>Competitive Pressure and Pricing Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Pharma\/Vaccines sector is experiencing intensifying competition from both domestic and international players. Pricing pressure \u2014 whether from low-cost Chinese imports, domestic capacity additions, or client negotiation \u2014 could force Panacea Biotec to offer discounts or increase marketing spend, compressing margins below the Q4 FY26 estimate range.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Governance_and_Reporting_Quality_Risk\"><\/span><strong>Governance and Reporting Quality Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Panacea Biotec operates as a smaller listed entity with limited institutional investor scrutiny compared to large-cap peers. Investors should review auditor qualifications, related-party transactions, promoter pledging data, and contingent liabilities in the Q4 FY26 annual results before drawing conclusions about long-term investment merit.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FY27_Guidance_Risk_and_Estimate_Revision\"><\/span><strong>FY27 Guidance Risk and Estimate Revision<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>If Panacea Biotec&#8217;s Q4 FY26 management commentary signals weaker-than-expected FY27 demand or margin compression, analyst estimate cuts would follow quickly given the limited coverage and thin investor base. The market&#8217;s reaction to guidance disappointment is typically sharper for smaller companies where sentiment can swing significantly on limited new information.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Panacea_Biotec_Share_Price_and_Analyst_Ratings\"><\/span><strong>Panacea Biotec Share Price and Analyst Ratings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160951\/share_analyst-58-1024x536.jpg\" alt=\"Panacea Biotec Share Price &amp; Analyst Ratings | Source: NSE\/BSE, Broker Notes\" class=\"wp-image-73492\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160951\/share_analyst-58-1024x536.jpg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160951\/share_analyst-58-300x157.jpg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160951\/share_analyst-58-768x402.jpg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160951\/share_analyst-58-900x471.jpg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160951\/share_analyst-58-600x314.jpg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160951\/share_analyst-58-150x79.jpg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160951\/share_analyst-58.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><p>Panacea Biotec is trading at Rs 328 as of early April 2026, against a 52-week high of Rs 520 and 52-week low of Rs 265. Market cap stands at Rs 2,380 Cr. The 1-year return of -30% reflects sector headwinds alongside company-specific factors. Analyst price targets range from the conservative to the optimistic, reflecting differing views on recovery pace and FY27 earnings potential.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Brokerage<\/strong><\/td><td><strong>Rating<\/strong><\/td><td><strong>Target Price<\/strong><\/td><td><strong>Thesis<\/strong><\/td><\/tr><tr><td>MOFSL<\/td><td>Buy<\/td><td>Rs 420<\/td><td>Vaccine CDMO play<\/td><\/tr><tr><td>YES Securities<\/td><td>Buy<\/td><td>Rs 440<\/td><td>Export market recovery<\/td><\/tr><tr><td>JM Financial<\/td><td>Neutral<\/td><td>Rs 380<\/td><td>Execution watch<\/td><\/tr><\/tbody><\/table><\/figure><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Panacea Biotec&#8217;s live price and receive real-time Q4 result alerts.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Panacea Biotec Q4 FY26 results will reflect its vaccine manufacturing and CDMO capabilities in a post-pandemic environment. At Rs 328, the stock is 37% below its 52-week high of Rs 520. Revenue toward Rs 300 Cr with PAT above Rs 22 Cr would confirm business recovery. Export market order visibility will be the key catalyst for re-rating. Consult a SEBI-registered advisor before investing.<\/p><p>This content is published by Univest, a SEBI-registered research and advisory platform. All analyst estimates and price targets cited are from publicly available broker notes. Past performance is not indicative of future results. Investors should conduct independent due diligence before making any investment decisions.<\/p><p>For more Q4 FY26 previews visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Panacea_Biotec_Q4_results_2026_date\"><\/span><strong>What is the Panacea Biotec Q4 results 2026 date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Panacea Biotec Q4 FY26 results are scheduled for May 2026 (Expected). The board will meet to approve audited financial statements for the quarter ended March 31, 2026.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Panacea_Biotec_Q4_FY26_PAT_estimate\"><\/span><strong>What is the Panacea Biotec Q4 FY26 PAT estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analysts estimate Panacea Biotec Q4 FY26 PAT in the range of Rs 18\u201328 Cr, on revenue of Rs 280\u2013320 Cr and margin of EBITDA 12\u201316%. Actual results may differ from these estimates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Panacea_Biotecs_share_price_ahead_of_Q4_results\"><\/span><strong>What is Panacea Biotec&#8217;s share price ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Panacea Biotec shares are trading at approximately Rs 328 as of early April 2026. The 52-week high is Rs 520 and 52-week low is Rs 265. The one-year return is -30% and market cap stands at Rs 2,380 Cr.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Will_Panacea_Biotec_declare_a_dividend_in_Q4_2026\"><\/span><strong>Will Panacea Biotec declare a dividend in Q4 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Panacea Biotec is expected to consider Rs 2\u20133 per share at the Q4 FY26 board meeting on May 2026 (Expected). The dividend decision reflects management&#8217;s confidence in FY26 free cash flow generation.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Which_analysts_have_a_Buy_rating_on_Panacea_Biotec\"><\/span><strong>Which analysts have a Buy rating on Panacea Biotec?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>MOFSL (target Rs 420), YES Securities (target Rs 440) ahead of Q4 FY26 results.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_were_Panacea_Biotec_Q3_FY26_results\"><\/span><strong>What were Panacea Biotec Q3 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>In Q3 FY26, Panacea Biotec reported revenue of Rs 255 Cr and PAT of Rs 15 Cr with margins at EBITDA 13.5%. These provided the base for Q4 FY26 analyst estimates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"When_do_Infosys_and_TCS_announce_Q4_results_2026\"><\/span><strong>When do Infosys and TCS announce Q4 results 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>TCS announced Q4 FY26 results on April 9, 2026 \u2014 full preview at <a href=\"https:\/\/univest.in\/blogs\/tcs-q4-results-2026-date-preview\">TCS Q4 Results 2026<\/a>. <a href=\"https:\/\/univest.in\/blogs\/infosys-q4-results-2026-date-preview\">Infosys<\/a> announced results on April 23, 2026.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_Panacea_Biotec_a_good_investment_ahead_of_Q4_results\"><\/span><strong>Is Panacea Biotec a good investment ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Panacea Biotec at Rs 328 offers a risk-reward contingent on Q4 execution and FY27 guidance. Investors should review analyst estimates, monitor the results announcement, and consult a SEBI-registered advisor before making investment decisions.<\/p><p>Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE\/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/motisons-jewellers-q4-results-2026\">Motisons Jewellers Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/motilal-oswal-financial-services-q4-results-2026\">Motilal Oswal Financial Services Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/moschip-technologies-q4-results-2026\">Moschip Technologies Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/morepen-laboratories-q4-results-2026\">Morepen Laboratories Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/morarjee-textiles-q4-results-2026\">Morarjee Textiles Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Panacea Biotec (NSE: PANACEABIO) is preparing to announce its Q4 FY26 financial results for the quarter ended March 31, 2026. With Panacea Biotec trading at Rs 328 \u2014 against a 52-week high of Rs 520 and a 1-year return of -30% \u2014 the Q4 FY26 results will be a pivotal event for investors tracking the<\/p>\n","protected":false},"author":23,"featured_media":73490,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3983],"class_list":["post-73485","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-q4-results-2026"],"metadata":{"_edit_lock":["1776422524:23"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:6:{s:63:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-1088.jpeg\";a:2:{s:2:\"id\";i:73489;s:11:\"source_type\";s:13:\"media-library\";}s:95:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160807\/image-1088.jpeg\";a:2:{s:2:\"id\";i:73489;s:11:\"source_type\";s:13:\"media-library\";}s:68:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/share_analyst-58.jpg\";a:2:{s:2:\"id\";i:73492;s:11:\"source_type\";s:13:\"media-library\";}s:77:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/share_analyst-58-1024x536.jpg\";a:2:{s:2:\"id\";i:73492;s:11:\"source_type\";s:13:\"media-library\";}s:100:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160951\/share_analyst-58.jpg\";a:2:{s:2:\"id\";i:73492;s:11:\"source_type\";s:13:\"media-library\";}s:109:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160951\/share_analyst-58-1024x536.jpg\";a:2:{s:2:\"id\";i:73492;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_primary_category":["842"],"rank_math_seo_score":["81"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"rank_math_title":["Panacea Biotec Q4 Results 2026: Date, Revenue And Vaccine Estimates"],"rank_math_description":["Panacea Biotec Q4 results expected May 2026. Revenue estimate Rs 280\u2013320 Cr, PAT Rs 18\u201328 Cr. Vaccine CDMO and export market recovery preview with analyst targets."],"rank_math_focus_keyword":["Panacea Biotec Q4 Results"],"_thumbnail_id":["73490"],"_edit_last":["23"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["8427"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/17160819\/Panacea-Biotec-Q4-Results.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/73485","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=73485"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/73485\/revisions"}],"predecessor-version":[{"id":73494,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/73485\/revisions\/73494"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/73490"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=73485"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=73485"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=73485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}